{"id":"NCT04085601","sponsor":"Apellis Pharmaceuticals, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH","officialTitle":"A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-08-27","primaryCompletion":"2021-06-23","completion":"2021-06-23","firstPosted":"2019-09-11","resultsPosted":"2022-10-21","lastUpdate":"2022-10-21"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria"],"interventions":[{"type":"DRUG","name":"APL-2","otherNames":[]}],"arms":[{"label":"Standard of Care (SOC) excluding complement inhibitors","type":"NO_INTERVENTION"},{"label":"1,080mg APL-2 administered subcutaneously twice weekly","type":"EXPERIMENTAL"}],"summary":"Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .","primaryOutcome":{"measure":"Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization","timeFrame":"From Baseline (Day 1) up to Week 26","effectByArm":[{"arm":"Pegcetacoplan","deltaMin":30,"sd":null},{"arm":"Standard of Care","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":4},"locations":{"siteCount":30,"countries":["Colombia","Hong Kong","Malaysia","Mexico","Peru","Philippines","Poland","Serbia","Singapore","Thailand"]},"refs":{"pmids":["40720060","39079163","38727860","37655691","37052120","36848639","36750531","34922648"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":46},"commonTop":["Hypokalaemia","Pain in extremity","Arthralgia","Dizziness","Pyrexia"]}}